DOI: https://doi.org/10.22141/1608-1706.6.17.2016.88614

The Value of Non-Steroidal Anti-Inflammatory Drugs in the Conservative Treatment of Coxarthrosis

S.E. Bondarenko

Abstract


Coxarthrosis is an actual problem of modern health care due to the high prevalence of this pathology, the diversity of its etiologic factors, chronicity and the lack of effectiveness of conservative treatment, which in most cases results in the total joint replacement. This article, based on our medical practice and the guidelines of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, presents the approaches to the drug treatment of coxarthrosis, the role and importance of non-steroidal anti-inflammatory drugs in its conservative management.


Keywords


coxarthrosis; non-steroidal anti-inflammatory drugs; lornoxicam; conservative therapy

References


Шуба В.Й. Остеоартроз: ранняя диагностика и лечение [Електронний ресурс] // Український медичний часопис. — 2016. — № 1. — Режим доступу до журн.: http://www.umj.com.ua/article/93870/osteoartroz-rannya-diagnostika-ta-likuvannya

Reginster J.Y. Introduction and WHO perspective on the global burden of musculoskeletal conditions / J.Y. Reginster, N.G. Khaltaev // Rheumatology (Oxford). — 2002. — № 41, Suppl. 1. — P. 1-2.

Hamerman D. Clinical implications of osteoarthritis and ageing / D. Hamerman // Ann. Rheum Dis. — 1995. — № 54 (2). — P. 82-85.

Prevalence of Total Hip and Knee Replacement in the United States / H.M. Kremers, D.R. Larson, C.S. Crowson [et al.] // J. Bone Joint Surg. Am. — 2015. — № 97 (17). — P. 1386-1397.

OARSI guidelines for the non-surgical management of knee osteoarthritis / T.E. McAlindon, R.R. Bannuru, M.C. Sullivan [et al.] // Osteoarthritis and Cartilage. — 2014. — № 22 (3). — P. 363-388.

An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) / O. Bruyère, C. Cooper, J.P. Pelletier [et al.] // Semin. Arthritis Rheum. — 2014. — № 44 (3). — P. 253-263.

Treatment of Osteoarthritis (OA) of the Knee [Електронний ресурс] / Evidence-based guideline 2nd edition. — 2013. — 1234 p. — Режим доступу до журн.: http://www.aaos.org/cc_files/aaosorg/research/guidelines/treatmentofosteoarthritisofthekneeguideline.pdf

A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting / O. Bruyère, C. Cooper, J.P. Pelletier [et al.] // Semin. Arthritis Rheum. — 2016. — № 45 (4 Suppl.). — P. S3-11.

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies / C.O. Bingham 3rd, A.I. Sebba, B.R. Rubin [et al.] // Rheumatology (Oxford). — 2007. — № 46 (3). — P. 496-507.

Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial / C.W. Wiesenhutter, J.A. Boice, A. Ko [et al.] // Mayo Clin. Proc. — 2005. — № 80 (4). — P. 470-479.

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial / A.T. Leung, K. Malmstrom, A.E. Gallacher [et al.] // Curr. Med. Res. Opin. — 2002. — № 18 (2). — P. 49-58.

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis / J. Zacher, D. Feldman, R. Gerli [et al.] // Curr. Med. Res. Opin. — 2003. — № 19 (8). — P. 725-736.

Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489] / S.P. Curtis, B. Bockow, C. Fisher [et al.] // BMC Musculoskelet Disord. — 2005. — № 6. — P. 58.

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations / A. Lanas, L.A. Garcia-Rodriguez, M.T. Arroyo [et al.] // Gut. — 2006. — № 55. — P. 1731-1738.

Kullich W., Klein G. // Akt. Rheumatol. — 1992. — 17. — 128-132.

Berg J. et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro // Inflamm. Res. — 1999. — 48 (7). — 369-79.

Pruss T. et al. // Postgrad. Med. J. — 1990. — 66 (4). —18-21.

Kidd B., Frenzel W. A Multicenter, randomized, dable blind stady comparing Lornoxicam with Diclofenac in osteoarthritis // J. Rheumatol. — 1996. — 23. — 1605-11.




Copyright (c) 2017 TRAUMA

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта